These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18031178)

  • 1. Respirable antisense oligonucleotide (RASON) therapy for allergic asthma.
    Metzger WJ; Nyce JW
    BioDrugs; 1999 Oct; 12(4):237-43. PubMed ID: 18031178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RASONs: a novel antisense oligonucleotide therapeutic approach for asthma.
    Sandrasagra A; Tang L; Leonard SA; Teng K; Li Y; Mannion JC; Nyce JW
    Expert Opin Biol Ther; 2001 Nov; 1(6):979-83. PubMed ID: 11728229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respirable antisense oligonucleotides: a new drug class for respiratory disease.
    Tanaka M; Nyce JW
    Respir Res; 2001; 2(1):5-9. PubMed ID: 11686859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma.
    Ball HA; Sandrasagra A; Tang L; Van Scott M; Wild J; Nyce JW
    Am J Pharmacogenomics; 2003; 3(2):97-106. PubMed ID: 12749727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma.
    Ali S; Leonard SA; Kukoly CA; Metzger WJ; Wooles WR; McGinty JF; Tanaka M; Sandrasagra A; Nyce JW
    Am J Respir Crit Care Med; 2001 Mar; 163(4):989-93. PubMed ID: 11282778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of respirable antisense therapeutics for asthma.
    Sandrasagra A; Leonard SA; Tang L; Teng K; Li Y; Ball HA; Mannion JC; Nyce JW
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):177-81. PubMed ID: 12162700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases.
    Nyce JW
    Expert Opin Investig Drugs; 1997 Sep; 6(9):1149-56. PubMed ID: 15991889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.
    Nyce J
    Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):533-6. PubMed ID: 14752337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA.
    Dreyfus DH; Matczuk A; Fuleihan R
    Int Immunopharmacol; 2004 Aug; 4(8):1015-27. PubMed ID: 15222976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: EPI-2010, EpiGenesis.
    Zhang Z
    Curr Opin Mol Ther; 2002 Jun; 4(3):275-80. PubMed ID: 12139314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA antisense therapy for asthma in an animal model.
    Nyce JW; Metzger WJ
    Nature; 1997 Feb; 385(6618):721-5. PubMed ID: 9034188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide therapy of allergic asthma.
    Metzger WJ; Nyce JW
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 1):260-6. PubMed ID: 10452739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma.
    Obiefuna PC; Batra VK; Nadeem A; Borron P; Wilson CN; Mustafa SJ
    J Pharmacol Exp Ther; 2005 Oct; 315(1):329-36. PubMed ID: 16020631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders.
    Ball HA; Van Scott MR; Robinson CB
    Clin Rev Allergy Immunol; 2004 Dec; 27(3):207-17. PubMed ID: 15630157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of antisense oligodeoxynucleotides for transplantation.
    Stepkowski SM
    Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of antisense therapeutic interventions for molecular biological targets in asthma.
    Popescu FD; Popescu F
    Biologics; 2007 Sep; 1(3):271-83. PubMed ID: 19707336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation.
    Nadeem A; Obiefuna PC; Wilson CN; Mustafa SJ
    Eur J Pharmacol; 2006 Dec; 551(1-3):116-24. PubMed ID: 17027749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of antisense-endothelin converting enzyme RNA on interleukin-5 released from dust mite-challenged peripheral blood mononuclear cells in patients with allergic asthma].
    Li L; Xu J; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Sep; 26(9):531-4. PubMed ID: 14521755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
    Temsamani J; Roskey A; Chaix C; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.